BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2025 9:58:09 AM | Browse: 173 | Download: 282
 |
Received |
|
2025-07-14 03:03 |
 |
Peer-Review Started |
|
2025-07-14 03:03 |
 |
First Decision by Editorial Office Director |
|
2025-07-28 08:27 |
 |
Return for Revision |
|
2025-07-28 08:27 |
 |
Revised |
|
2025-07-29 19:18 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2025-08-25 03:52 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-08-25 08:41 |
 |
Articles in Press |
|
2025-08-25 08:41 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-10-14 06:42 |
 |
Publish the Manuscript Online |
|
2025-10-24 09:58 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Dual versus single antiplatelet therapy after lower extremity revascularization in peripheral artery disease: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mohammad Maroof Shahid, Debvarsha Mandal, Ashesh Das, Pershan Kumar, Nikil Kumar, Absar Mukhtar, Hooria Ejaz, Muhammad Soban Jaffar, Mavia Habib, Ayesha Afzal, Mirza Muhammad Hadeed Khawar and Ikra Rana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ikra Rana, MD, Department of Medicine, International School of Medicine, International University of Kyrgyzstan, 6 Street, Bishkek 720074, Kyrgyzstan. ikrarana100@gmail.com |
| Key Words |
Peripheral artery disease; Dual antiplatelet therapy; Single antiplatelet therapy; Lower extremity revascularization; Endovascular intervention; Surgical bypass; Cardiovascular outcomes; Bleeding risk |
| Core Tip |
This meta-analysis synthesizes evidence from randomized controlled trials and cohort studies to compare dual antiplatelet therapy (DAPT) and single antiplatelet therapy (SAPT) following lower extremity revascularization in patients with peripheral artery disease (PAD). The findings demonstrate that DAPT is associated with reduced cardiac mortality, myocardial infarction, and major reintervention risk compared to SAPT, without a significant increase in bleeding complications. These results support the short-term use of DAPT in PAD management post-revascularization and inform current clinical guidelines. |
| Publish Date |
2025-10-24 09:58 |
| Citation |
Shahid MM, Mandal D, Das A, Kumar P, Kumar N, Mukhtar A, Ejaz H, Jaffar MS, Habib M, Afzal A, Khawar MMH, Rana I. Dual versus single antiplatelet therapy after lower extremity revascularization in peripheral artery disease: A systematic review and meta-analysis. World J Cardiol 2025; 17(10): 111941 |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i10/111941.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i10.111941 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.